RxDoctor Payments Data

Nancy Zidek, MD

Family Medicine · Holton, KSNPI 1528048063

Payments from drug & device makers

$2,233in general payments, 2019–2025

Across 133 payments — averaging $16.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$296
  • AbbVie$222
  • Lilly USA, LLC$192
  • Novo Nordisk$171
  • Johnson & Johnson$161
  • Takeda Pharmaceuticals U.S.A., Inc.$99
  • plus $1K from 29 others

What the payments were for

  • Food & beverage$2,21999%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,233 in reported general payments places this provider in the 75th percentile of 1,469 family medicine providers in Kansas.

See all family medicine providers in Kansas

Medicare billing

Part B allowed, 2024
$7,861
Medicare patients
52
Services billed
131

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ArexvyRsvpref3 Antigen/As01e/Pf123$38,208
ShingrixVaricella-Zoster Ge/As01b/Pf107$23,646
TrulicityDulaglutide18$19,579
Fentanyl74$19,108
JardianceEmpagliflozin29$17,390
MounjaroTirzepatide12$13,637
EliquisApixaban33$12,789
OzempicSemaglutide13$12,607
XareltoRivaroxaban24$10,951
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog36$9,979
MyrbetriqMirabegron32$9,918
Xtampza ErOxycodone Myristate12$7,637
GemtesaVibegron30$7,206
JanumetSitagliptin Phos/Metformin Hcl12$6,173
JanuviaSitagliptin Phosphate12$6,173

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKArexvy, Shingrix, Breo Ellipta, Twinrix$33$69,390256 claims
Lilly USA, LLCTrulicity, Mounjaro$192$33,21630 claims
Boehringer IngelheimJardiance$76$17,39029 claims
PfizerEliquis$24$12,78933 claims
Novo NordiskOzempic$171$12,60713 claims
MerckJanumet, Januvia$15$12,34724 claims
Johnson & JohnsonXarelto$161$10,95124 claims
Astellas Pharma US IncMyrbetriq$66$9,91832 claims
Sumitomo Pharma America, Inc.Gemtesa$29$7,20630 claims
AbbVieSynthroid$222$71022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,469 family medicine providers in Kansas.

Other family medicine in Holton

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →